NCT01395641View on ClinicalTrials.gov

A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

December 18, 2020

Study Completion Date

March 7, 2022

Conditions
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Interventions
DRUG

gene therapy

AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

PTC Therapeutics
All Listed Sponsors
collaborator

PTC Therapeutics

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT01395641 - A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC | Biotech Hunter | Biotech Hunter